Myovant Sciences Ltd (NYSE:MYOV) shares fell 5.4% during trading on Friday . The company traded as low as $6.33 and last traded at $6.15, 14,582 shares changed hands during mid-day trading. A decline of 95% from the average session volume of 300,782 shares. The stock had previously closed at $6.50.

A number of brokerages have recently commented on MYOV. ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday, September 6th. Goldman Sachs Group began coverage on Myovant Sciences in a research report on Wednesday, August 28th. They issued a “buy” rating and a $20.00 price target on the stock. Zacks Investment Research raised Myovant Sciences from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research report on Saturday, August 10th. Finally, Leerink Swann began coverage on Myovant Sciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price target on the stock. Eleven analysts have rated the stock with a buy rating, Myovant Sciences has an average rating of “Buy” and a consensus target price of $24.28.

The company has a market capitalization of $635.42 million, a PE ratio of -1.51 and a beta of 0.96. The business’s fifty day moving average is $7.43 and its two-hundred day moving average is $13.63. The company has a current ratio of 3.42, a quick ratio of 3.42 and a debt-to-equity ratio of 1.24.

Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.06. As a group, equities research analysts anticipate that Myovant Sciences Ltd will post -3.13 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Atria Investments LLC raised its holdings in Myovant Sciences by 87.9% in the 2nd quarter. Atria Investments LLC now owns 22,915 shares of the company’s stock worth $162,000 after acquiring an additional 10,720 shares during the last quarter. Platinum Investment Management Ltd. raised its holdings in Myovant Sciences by 62.7% in the 2nd quarter. Platinum Investment Management Ltd. now owns 238,398 shares of the company’s stock worth $2,158,000 after acquiring an additional 91,846 shares during the last quarter. First Manhattan Co. raised its holdings in Myovant Sciences by 2,146.6% in the 2nd quarter. First Manhattan Co. now owns 400,000 shares of the company’s stock worth $3,620,000 after acquiring an additional 382,195 shares during the last quarter. United Services Automobile Association purchased a new position in Myovant Sciences in the 2nd quarter worth approximately $690,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in Myovant Sciences by 33.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,086,893 shares of the company’s stock worth $9,836,000 after acquiring an additional 274,745 shares during the last quarter. Institutional investors own 40.29% of the company’s stock.

About Myovant Sciences (NYSE:MYOV)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Recommended Story: How Investors Use a Balance Sheet

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.